. 2021 Feb 27;48(7):2200–2211. doi: 10.1007/s00259-021-05246-x

Table 2.

Overview of the primary outcomes (changes in diagnosis and changes in diagnostic confidence) in the whole sample and in the three cognitive stage groups (SCD, MCI, dementia)

Primary outcomes	Change in diagnosis (%, p value)	Change in diagnostic confidence (%, p value)
First exam	Amyloid-PET	28%, p = 0.006	17%, p = 1.00	35%, p = 0.008	23%, p = 0.343	+18%, p < 0.001	+23%, p < 0.001	+19%, p < 0.001	+14%, p < 0.001
Tau-PET	28%, p < 0.001	17%, p = 0.617	39%, p < 0.001	16%, p = 0.023	+19%, p < 0.001	+26%, p < 0.001	+22%, p < 0.001	+10%, p < 0.001
Second exam	Amyloid-PET	6%, p = 0.077	0%	6%, p = 0.134	9%, p = 0.617	+4%, p < 0.001	+3%, p = 1.00	+3%, p = 0.114	+5%, p = 0.005
Tau-PET	9%, p = 0.149	0%	12%, p = 0.289	9%, p = 0.617	+5%, p < 0.001	+6%, p = 0.007	+4%, p = 0.005	+ 6%, p = 0.001

Primary outcomes

Change in diagnosis (%, p value)

Change in diagnostic confidence (%, p value)

Whole sample
n = 136

SCD
n = 24

MCI
n = 69

Dementia
n = 43

Whole sample
n = 136

SCD
n = 24

MCI
n = 69

Dementia
n = 43

First exam

Amyloid-PET

28%,

p = 0.006

17%,

p = 1.00

35%,

p = 0.008

23%,

p = 0.343

+18%,

p < 0.001

+23%,

p < 0.001

+19%,

p < 0.001

+14%,

p < 0.001

Tau-PET

28%,

p < 0.001

17%,

p = 0.617

39%,

p < 0.001

16%,

p = 0.023

+19%,

p < 0.001

+26%,

p < 0.001

+22%,

p < 0.001

+10%,

p < 0.001

Second exam

Amyloid-PET

6%,

p = 0.077

6%,

p = 0.134

9%,

p = 0.617

+4%,

p < 0.001

+3%,

p = 1.00

+3%,

p = 0.114

+5%,

p = 0.005

Tau-PET

9%,

p = 0.149

12%,

p = 0.289

9%,

p = 0.617

+5%,

p < 0.001

+6%,

p = 0.007

+4%,

p = 0.005

+ 6%,

p = 0.001

Bold p values denote statistical significance (p < 0.05)